Iga Swiatek suspended after testing positive for banned substance

Iga Swiatek has accepted a suspension after testing positive for a banned substance

Iga Swiatek has accepted a one-month suspension after testing positive for the banned substance trimetazidine (TMZ) in August of this year. The International Tennis Integrity Agency announced the news on Thursday, confirming that they accepted the positive test was the result of contamination via medication. An ITIA investigation resulting in a finding of "No Significant Fault or Negligence". Swiatek has already served a provisional suspension which will count towards her one-month ban.

Swiatek tested positive for "low levels" of the prohibited substance in an out-of-competition urine sample on August 12 2024. The ITIA then sent the world No. 2 a pre-charge notice for an Anti-Doping Rule Violation a month later. TMZ is classified as "a non-Specified substance" and the 23-year-old did not possess a valid therapeutic use exemption for the substance. She was automatically given a provisional suspension from September 12. Swiatek appealed the provisional suspension to an independent tribunal on September 22 and identified the source of the contamination. The ITIA said: "Whilst the appeal was being considered, the player notified the independent tribunal chair that they had identified that a regulated non-prescription melatonin medicine, manufactured and regulated in Poland, was contaminated with TMZ and hence was the source of their positive test. "The contamination was confirmed by the independent and WADA-accredited Sports Medicine Research & Testing Laboratory (SMRTL) in Utah, USA and the scenario was verified by an independent scientific expert from another WADA-accredited laboratory."

Iga Swiatek has forfeited her prize money from the Cincinnati Open as a result

Stay up-to-date with the latest Tennis news Join us on WhatsApp Our community members are treated to special offers, promotions, and adverts from us and our partners. You can check out at any time. Read our Privacy Policy

SUBSCRIBE Invalid email We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. This may include adverts from us and 3rd parties based on our understanding. You can unsubscribe at any time. Read our Privacy Policy

The ITIA did not oppose to Swiatek's provisional suspension being lifted on October 4. Because her appeal was successful and was requested in the allocated 10-day timeframe, news of the Polish star's provisional suspension was not made public. The five-time Grand Slam champion missed three events during her provisional suspension - the WTA 500 in Korea and two WTA 100 events in Beijing and Wuhan. The Wuhan tournament started on October 7 but she was still suspended during the tournament deadline days earlier. At the time, Swiatek said she was skipping the tournaments to adjust to changes in her coaching team after parting ways with Tomasz Wiktorowski. Following a full investigation, the ITIA has "accepted that the positive test was caused by the contamination of a regulated non-prescription medication (melatonin), manufactured and sold in Poland that the player had been taking for jet lag and sleep issues, and that the violation was therefore not intentional." The ITIA interviewed Swiatek and her entourage, and used analysis from two WADA-accredited laboratories.

Click here to read article